背景:研究表明,全变异型阿尔茨海默病(AD)和额颞叶痴呆(FTD)的患病率均随年龄增长而增加,甚至在65岁之前。然而,目前尚不清楚他们不同的临床表现是否都以相同的方式随年龄增加患病率。
方法:我们在一项以人群为基础的研究中,研究了5岁年龄组青年型AD和FTD不同临床表现的患病率,确定了摩德纳省所有诊断为AD和FTD的痴呆患者以及65岁之前的症状。意大利。通过使用累积发生的回归模型,我们还估算了年龄特异性患病率,并比较了临床表现的生长曲线.
结果:所有变异型AD的患病率随年龄增加而增加,从40-44岁年龄组的18/1,000,000到60-64岁年龄组的1411/1,000,000。所有变异型FTD的患病率也随着年龄的增长而增加,从18/1,000,000到866/1,000,000。对每种临床表现的年龄特异性患病率功能的估计表明,非典型非遗忘型AD和失语症性FTD在早期年龄增长最多,其次是FTD的行为变体(bvFTD)。然后,与AD和FTD的所有其他临床变异相比,在60岁左右,遗忘型AD占据了主导地位,其年龄特异性患病率继续不成比例地增加,which,相反,患病率开始下降。
结论:遗忘型AD是随着年龄增长而增加的临床表现,其次是bvFTD,这表明,在相同的神经退行性疾病中,衰老的影响存在差异。
BACKGROUND: Studies have shown that the prevalence of all-variants Alzheimer\'s disease (AD) and frontotemporal dementia (FTD) both increase with age, even before the age of 65. However, it is not known whether their different clinical presentations all increase in prevalence with age in the same way.
METHODS: We studied the prevalence of the different clinical presentations of young-onset AD and FTD by 5-year age groups in a population-based study identifying all dementia patients with a diagnosis of AD and FTD and symptoms onset before age 65 in the Modena province, Italy. By using regression models of cumulative occurrences, we also estimated age-specific prevalence and compared the growth curves of the clinical presentations.
RESULTS: The prevalence of all-variants AD increased with age, from 18/1,000,000 in the 40-44 age group to 1411/1,000,000 in the 60-64 age group. The prevalence of all-variants FTD also increased with age, from 18/1,000,000 to 866/1,000,000. An estimation of age-specific prevalence functions of each clinical presentation showed that atypical non-amnestic AD and aphasic FTD grew the most in early ages, followed by the behavioural variant of FTD (bvFTD). Then, around the age of 60, amnestic AD took over and its age-specific prevalence continued to increase disproportionally compared to all the other clinical variants of AD and FTD, which, instead, started to decrease in prevalence.
CONCLUSIONS: Amnestic AD is the clinical presentation that increases the most with advancing age, followed by bvFTD, suggesting that there is a differential vulnerability to the effect of ageing within the same neurodegenerative disease.